BRCAness revisited

By C. Lord, Alan Ashworth. Nature Reviews. Cancer, 2016

1,160 citations recorded by the source corpus.

Subfields: Genetics, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/6402460a2b9b06bee96aff135ff63d254093fbca

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. Alan Ashworth
2. Andrew Tutt
3. Michael R. Stratton
4. Ewan Birney
5. Eytan Ruppin
6. Arul M. Chinnaiyan
7. Peter J. Campbell
8. Serafim Batzoglou

In Molecular Biology

1. Alan Ashworth
2. Andrew Tutt
3. D. Fruman
4. Peter J. Campbell
5. S. Nik-Zainal
6. B. Hopkins
7. R. DePinho
8. R. Abraham

In Oncology

1. Peter J. Campbell
2. S. Nik-Zainal
3. Alan Ashworth
4. Michael R. Stratton
5. A. Richardson
6. Lewis C. Cantley
7. R. Abraham
8. R. DePinho

Citations in the corpus

• Precision Oncology: The Road Ahead (2017, background): “notable example is that of BRCA-associated signatures [73], where tumors (such as breast, ovarian or prostate tumors among others [66, 73]) sharing similar molecular signatures to BRCA-mutant tumors may also respond to similar therapeutic approaches, even when lacking specific BRCA mutations [73–75]”
• Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. (2018, positive): “Cells bearing homologous recombination repair defects develop genomic scars (reviewed in Lord and Ashworth, 2016), including deletions with homology at both ends of the deleted region.”
• HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational-signatures (2017, background): “…demonstrate BRCAness and could be selectively sensitive to PARP inhibitors is likely not limited to the small proportion of familial breast and ovarian cancers with BRCA1 or BRCA2 mutations but extends to a larger fraction of sporadic breast and ovarian cancers, as well as other cancer types 25 .”
• The PI3K pathway in human disease (2017, positive): “PARP inhibitors have shown clinically significant activity in BRCA1- or BRCA2-mutated ovarian cancers (later-stage studies in BRCA-deficient TNBC patients are ongoing) due to a synthetic lethal mechanism in cells deficient in homologous combination-mediated DNA repair (Lord and Ashworth, 2016).”
• Genetics and biology of prostate cancer (2018, background): “Olaparib, a Food and Drug Administration (FDA)- approved oral PARP inhibitor for BRCA-deficient cancers (Bryant et al. 2005; Farmer et al. 2005), also shows promising clinical activity in cancers possessing mutations in other DNA repair genes (Lord and Ashworth 2016).”